Drug
Lenvatinib clinical trials
Also written Lenvima, E7080 and MK-7902.
- studies test it
- 359
- open now
- 137
- in phase 3
- 42
- first study started
- 2005
Keep track of what changes. Save the lenvatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
359 studies that test it; most in 2021 (47)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 12 |
| 2017 | 13 |
| 2018 | 20 |
| 2019 | 27 |
| 2020 | 33 |
| 2021 | 47 |
| 2022 | 43 |
| 2023 | 40 |
| 2024 | 30 |
| 2025 | 29 |
| 2026 | 32 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 68
- Phase 2
- 254
- Phase 3
- 42
- Phase 4
- 7
- No phase
- 21
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 12
Who runs them
Industry 101 · Other 258
Eisai Inc. (33) · Merck Sharp & Dohme LLC (29) · Sun Yat-sen University (23) · Fudan University (18) · Eisai Co., Ltd. (12) · Peking Union Medical College Hospital (12) · M.D. Anderson Cancer Center (10) · Tianjin Medical University Cancer Institute and Hospital (8)
Often tested with
Tested in the same studies.
Pembrolizumab (89) · Tislelizumab (23) · Sintilimab (19) · Everolimus (13) · Paclitaxel (11) · Durvalumab (11) · Toripalimab (11) · Immune Checkpoint Inhibitors (10)
Studies
Open first, then newest update. How each study uses lenvatinib is read from its arms, and is right about nine times in ten.
Testing it · 359
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Written as Lenvatinib
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingPhase 1/2GI Innovation, Inc.NCT04977453Written as Lenvatinib
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Written as Lenvatinib
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingPhase 2Tongji HospitalNCT07417501Written as Lenvatinib plus PD-1 Inhibitor
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05064280Written as Lenvatinib
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07847359Written as Lenvatinib
- Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingPhase 2Yonsei UniversityNCT07843901Written as Lenvatinib
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingPhase 2University of MiamiNCT07594015Written as Lenvatinib
- Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingPhase 2Peking Union Medical College HospitalNCT07835893Written as Lenvatinib
- PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingPhase 2Chang Gung Memorial HospitalNCT07827807Written as Lenvatinib
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07776080Written as Lenvatinib
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingPhase 2Georgetown UniversityNCT04865887Written as Lenvatinib
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingPhase 2Fudan UniversityNCT07256223Written as Envafolimab+Lenvatinib
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingPhase 1/2Michael J. Dennis, MDNCT05774899Written as Lenvatinib
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Donafenib + lenvatinib+apatinib
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingPhase 2Tongji HospitalNCT06187961Written as Lenvatinib
- Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT05733715Written as Lenvatinib tablet
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06880523Written as Lenvatinib
- STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingPhase 2Dongguan People's HospitalNCT07754734Written as Lenvatinib
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT07475026Written as Lenvatinib
See all 359 studies that test lenvatinib →
Given in every arm · 78 — lenvatinib is usual care beside what is tested
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Lenvatinib
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06253494Written as Lenvatinib
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07874321Written as Lenvatinib
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT05319730Written as Lenvatinib
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingPhase 2CatalYm GmbHNCT07219459Written as Lenvatinib
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Not yet recruitingPhase 2Fudan UniversityNCT07829874Written as Lenvatinib
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07829926Written as Lenvatinib
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingPhase 2Shunda DuNCT07832006Written as Lenvatinib
- A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCCNot yet recruitingPhase 1/2Zhejiang Haichang Biotech Co., Ltd.NCT07540832Written as Lenvatinb
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Written as Lenvatinib
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05168163Written as Lenvatinib
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441Written as Lenvatinib
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingPhase 1/2Eisai Inc.NCT04300556Written as Lenvatinib
- Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyRecruitingPhase 2CHA UniversityNCT07493668Written as Lenvatinib
- Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell CarcinomaNot yet recruitingPhase 2Vall d'Hebron Institute of OncologyNCT07593040Written as Lenvatinb
- Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingPhase 3Tongji HospitalNCT07537946Written as Lenvatinib
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07487662Written as Lenvatinib
- Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCCNot yet recruitingPhase 2Fudan UniversityNCT07412054Written as Lenvatinib
- Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular CarcinomaRecruitingNot applicableBangladesh Medical UniversityNCT07408804Written as Lenvatinib
- A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingPhase 1Zhejiang UniversityNCT05155189Written as Lenvatinib
Showing 20 of 78.
As the comparator · 11 — what is tested is compared with lenvatinib
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular CarcinomaNot yet recruitingPhase 3BeOne MedicinesNCT07836530Written as Lenvatinib
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)RecruitingPhase 1AbbVieNCT06858813Written as Lenvatinib
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingPhase 2Fudan UniversityNCT07328009Written as Lenvatinib
- Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCCRecruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT06904196Written as Lenvatinib
- Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.RecruitingPhase 4Chen XiaopingNCT06311942Written as PD-1 inhibitors plus lenvatinib
- Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCCRecruitingPhase 3Second Affiliated Hospital of Guangzhou Medical UniversityNCT05608213Written as Lenvatinib
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607Written as lenvatinib
- CXD101 in Immunotherapy-related Liver CancerActive, not recruitingPhase 2Stephen Chan LamNCT05873244Written as Lenvatinib and Sorafenib
- Immunotherapy for Advanced Liver CancerSuspendedPhase 2/3Mirror Biologics, Inc.NCT05033522Written as Lenvatinib
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752Written as Lenvatinib
- The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Status unknownPhase 3Sun Yat-sen UniversityNCT04053985Written as Lenvatinib
Codes
What other systems call lenvatinib · ClinicalTrials.gg INT005329
- MeSH (NLM) C531958lenvatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) EE083865G2LENVATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1603296Confirmed FDA, Wikidata
- Wikidata Q6523413lenvatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95124LenvatinibOne source FDA
- DrugBank DB09078One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531958 | lenvatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | EE083865G2 | LENVATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1603296 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6523413 | lenvatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95124 | Lenvatinib | One source FDA |
| DrugBank | DB09078 | — | One source Wikidata |
Also registered as 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (UNII 269N24780P) and lenvatinib mesylate (UNII 3J78384F61 · RxNorm 1604346).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.